Keith Crandell

Arch Venture Partners XIII, LLC (Director) purchased 1,250,000 shares of KARD at $16.00; now holds 15,042,035 shares.

Arch Venture Partners XIII, LLC acquired 1,250,000 shares for $20,000,000.00, expanding its stake in Kardigan from 13,792,035 shares to 15,042,035 shares—a 9.1% increase in holdings. The purchase occurred at $16.00 per share, while the current market price stands at $22.03 as of 2026-06-24, four trading days after Kardigan's recent listing. This transaction represents a material expansion of an already substantial directorial position, with the entity now holding 15,042,035 shares outright.

ARCH Venture Partners XII acquires over 5M shares in SPTX IPO aftermath; major institutional vote of confidence at listing price

ARCH Venture Partners XII, a 10% beneficial owner of Seaport Therapeutics, executed a substantial open-market purchase of over 5 million shares on the stock's second trading day—a significant institutional commitment that coincides with the company's recent IPO. The timing is notable: the fund is buying at the listing price level after having already participated in the private placement rounds that likely seeded its beneficial ownership stake. This isn't insider knowledge driving the trade, but rather portfolio capital allocation—ARCH is doubling down on its conviction in the biotech therapeutics opportunity the company represents. The purchase reflects institutional confidence that the newly public shares offer fair value at current levels, which could signal that the market's initial pricing is reasonable from the fund's perspective.

ARCH Venture Fund XIII acquired 488,090 shares of LYEL at $25.61 for $12.5M, raising stake to 1.43M shares amid unprofitable fundamentals.

ARCH Venture Fund XIII, a 10% shareholder, purchased 488,090 shares at $25.61 on 2026-03-06, increasing its stake by 52.0% from 938,438 to 1.43M shares. The transaction occurred at a price 33.9% below the 52-week high of $38.60 but 228% above the 52-week low of $7.80, near recent momentum (+12.3% over 30 days, -12.9% over 90 days). The acquisition is notable given the company's deteriorating fundamentals: LYEL generated only $15.0K in latest-quarter revenue (annualized run-rate concerns), posted a net loss of $-38.8M, and experienced -53.1% annual revenue decline with sustained unprofitability. A venture capital anchor doubling down on a cash-burn biotech asset during a revenue collapse warrants scrutiny of the company's clinical/financing runway and the strategic rationale underlying this substantial $12.5M incremental commitment.

VC-backed insider ARCH Venture Partners XII bought 1,915,700 shares ($5.0M) at $2.61; 5 of 5 prior NMRA buys well-timed at 90d; cluster buy.

ARCH Venture Partners XII, a 10% owner, purchased 1,915,700 shares (1.92M shares) for $5.0M on 2025-10-27, raising holdings by 46.4% to 6,046,907 shares (6.05M shares). This is notable in context of the insider's trading history at NMRA: all 5 prior purchases (November 2023) were well-timed, with 90-day returns ranging from +48.5% to +61.2%. The insider's cross-ticker track record shows a 100.00% 90-day win rate across 20 prior buys with an average 90d return of +41.6%. Additionally, 2 other insiders bought within the past 14 days, forming a cluster-buy pattern. However, fundamentals remain challenged: the company reported net income of $-52,731,000.00 ($-52.7M) and remains unprofitable. Current price of $2.50 sits 81.7% below the 52-week high of $13.64, though the stock has recovered +42.0% over the past 30 days.

ARCH Venture Partners X bought 3,030,300 shares of PRME at $3.30 ($10.0M), boosting stake 94.7% to 6,230,300 shares

ARCH Venture Partners X, a 10% owner of Prime Medicine, purchased 3,030,300 shares at $3.30 on 2025-08-01 for $9,999,990.00, expanding its position from 3,200,000 to 6,230,300 shares. The company remains deeply unprofitable with a net loss of $-51,890,000.00 against minimal revenue of $1,454,000.00, though the stock has recovered +31.6% over 30 days and +140.5% over 90 days from a 52-week low. The prior ARCH purchase at this ticker on 2024-02-15 achieved positive returns at both the 30-day (+14.6%) and 90-day (+8.2%) intervals, establishing a successful historical precedent. A cluster of 3 other insiders also bought within the past 14 days, suggesting aligned investor interest despite the company's ongoing cash-burn profile.